These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29270781)

  • 1. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
    Lapolla A; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Simioni N; Bette C; Nicolucci A;
    Adv Ther; 2018 Feb; 35(2):243-253. PubMed ID: 29270781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
    McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
    Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Persistence with Liraglutide Among Patients with Type 2 Diabetes in Routine Clinical Practice--EVIDENCE: A Prospective, 2-Year Follow-Up, Observational, Post-Marketing Study.
    Gautier JF; Martinez L; Penfornis A; Eschwège E; Charpentier G; Huret B; Madani S; Gourdy P
    Adv Ther; 2015 Sep; 32(9):838-53. PubMed ID: 26424330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
    Simioni N; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Lapolla A; Bette C; Rossi MC;
    Acta Diabetol; 2018 Jun; 55(6):557-568. PubMed ID: 29527621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function.
    Rondinelli M; Rossi A; Gandolfi A; Saponaro F; Bucciarelli L; Adda G; Molinari C; Montefusco L; Specchia C; Chiara Rossi M; Scardapane M; Arosio M; Genovese S
    Clin Ther; 2017 Jan; 39(1):159-169. PubMed ID: 27939305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
    Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
    JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Persistence of Liraglutide Treatment Among Patients with Type 2 Diabetes Treated in Primary Care and Specialist Settings: A Subgroup Analysis from the EVIDENCE Study, a Prospective, 2-Year Follow-up, Observational, Post-Marketing Study.
    Martinez L; Penfornis A; Gautier JF; Eschwège E; Charpentier G; Bouzidi A; Gourdy P
    Adv Ther; 2017 Mar; 34(3):674-685. PubMed ID: 28138803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
    Persano M; Nollino L; Sambataro M; Rigato M; Negro I; Marchetto S; Paccagnella A
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):923-931. PubMed ID: 33577047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
    Chitnis AS; Ganz ML; Benjamin N; Langer J; Hammer M
    Adv Ther; 2014 Sep; 31(9):986-99. PubMed ID: 25245811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study.
    Germain N; Khalfallah Y; Estour B; Galusca B
    Diabetes Res Clin Pract; 2018 Mar; 137():20-27. PubMed ID: 29253625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinopathy risk factors in patients with type 2 diabetes on liraglutide.
    Mahzari MM; Alanazy AM; Feroz Z; Almani KM; Alghamdi MA; Almadani AS; Alzahrani MK; Alibrahim AR; Badri M
    Medicine (Baltimore); 2024 Jul; 103(29):e39026. PubMed ID: 39029073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
    Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
    Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes.
    Mirabelli M; Chiefari E; Caroleo P; Arcidiacono B; Corigliano DM; Giuliano S; Brunetti FS; Tanyolaç S; Foti DP; Puccio L; Brunetti A
    Int J Environ Res Public Health; 2019 Dec; 17(1):. PubMed ID: 31892206
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Vanderheiden A; Harrison L; Warshauer J; Li X; Adams-Huet B; Lingvay I
    JAMA Intern Med; 2016 Jul; 176(7):939-47. PubMed ID: 27273731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
    Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
    Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial design and baseline data for LIRA-PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting.
    Unger J; Allison DC; Carlton M; Lakkole K; Lowe D; Murphy G; Panda JK; Sargin M; Kaltoft M; Treppendahl MB; Zoghbi M;
    Diabetes Obes Metab; 2019 Jul; 21(7):1543-1550. PubMed ID: 30828917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.